11月29日，上海交通大学与上海第二医科大学强强合并20周年座谈会，在上海交通大学医学院（以下简 称"交医"）浦东校区其实图书馆举行。两个月前才启用的交医浦东校区占地435亩，与已历百年传承、 拥挤却雅致的重庆南路校区相比，显得开阔而崭新，建筑风格和格局却俨然是对老校"基因"的传承和放 大。 座谈会上，高朋满座。除了来自教育部、上海市政府的领导和相关部门负责人外，还有头发花白的老领 导和来自上海交通大学多个学院的师生代表、附属的医务人员代表等。虽然跨越不同校区、学科专业， 但教授、研究人员们相遇、交流中那份热烈与熟络，让人不由心生羡慕。 2005年，在教育部与上海市政府大力支持下，上海交通大学、上海第二医科大学正式合并。20年过 去，"物理叠加"正在蜕变为"化学融合"。用上海交通大学党委书记杨振斌的话说，是"实现了'1+1>2'的 双赢效应"；在上海交通大学医学院院长、中国工程院院士范先群看来，则是"从'双向奔赴'走向了'相互 成就'"。 研究高等教育的专家们说，这20年，为中国成功探索出了综合性大学建设高水平医学院的"交医模式"。 交叉融合，医工同行 "今年8月，我们的产品获批欧盟CE认证，可用于胸外、普外 ...

据悉，今年5月6日术锐单孔腔镜手术机器人获国家药品监督管理局(NMPA)医疗器械注册变更批准，适 用范围变更为"该产品由医师利用主从操控系统对于微创手术器械进行控制，用于泌尿外科、妇科、普 通外科、胸外科肺部腔镜手术操作"。自此，术锐单孔手术机器人成为国内首款、唯一覆盖泌尿外科、 妇科、普通外科、胸外科四大外科领域的单孔手术机器人。未来还将基于蛇形臂单孔技术优势，不断拓 展手术机器人的应用潜力。 术锐单孔腔镜手术机器人采用国际首创、自主知识产权的创新技术，具有运动范围广、负载能力强和可 靠性高等技术优势，可提高操作者精细化水平，减少手术创伤。 官网显示，术锐机器人由上海交通大学教授徐凯依据"科技成果、自主转化"相关政策创立。术锐机器人 是一家致力于自主研发、生产及商业化具备全球领先优势的微创腔镜手术机器人系统及配套器械产品的 高科技医疗器械企业，公司已完成北京、上海两地布局，生产制造基地位于北京，着眼未来的创新中心 位于上海。 据了解，术锐机器人掌握腔镜手术机器人全链条关键核心技术、拥有核心自主知识产权，截至2025年4 月末在全球范围内提出专利及申请超805项，已构筑全方位自主知识产权保护体系。作为国内单孔 ...

又一国产手术机器人公司，要 IPO 了。 证监会官网显示，北京术锐机器人股份有限公司（以下简称：术锐机器人）已在北京证监局完成 IPO 辅导备案登记，辅导机构为中信证 券。 来源：证监会 据公开资料，术锐机器人是一家由上海交通大学徐凯教授创立的高科技医疗器械企业，致力于单孔微创腔镜手术机器人系统的研发、生 产和商业化。 更为值得一提的是，继微创机器人于 2021 年正式登陆港交所后，早在 2023 年，精锋医疗、思哲睿、和华瑞博等多家国产手术机器人企 业就展开过一次上市潮，其中也包括术锐机器人，后者同中信证券签署上市辅导协议，也正式启动 A 股 IPO 进程。 只不过，时至今日，各家还尚未成功登陆二级市场，而术锐机器人亦以二次辅导揭开了新的 IPO 征途。 交大教授带队，做出一家领军企业。 这一技术基础亦成为了徐凯于 2014 年创办术锐机器人，并研发拓展出一系列关键技术与核心部件，全面进入了产业化的根基。 据悉，依托 " 对偶连续体机构 " 这一革新性设计，术锐机器人产品所搭载的高性能可形变手术臂动作不仅灵动精准，综合性能比肩国际 顶尖的单孔手术机器人水平，还一举打破国外多年技术垄断。 术锐机器人官网显示， ...

Core Viewpoint - Beijing Shurui Robot Co., Ltd. is preparing for an IPO, having completed the IPO guidance filing with the Beijing Securities Regulatory Bureau, with CITIC Securities as the guiding institution [1][3]. Company Overview - Founded on November 5, 2014, by Professor Xu Kai from Shanghai Jiao Tong University, Shurui Robot focuses on the research, production, and commercialization of single-port minimally invasive surgical robot systems [2][5]. - Xu Kai directly holds 22.74% of the company's shares and controls an additional 31.84% through various partnerships, totaling 54.58% of voting rights [2][8]. Industry Context - The company is part of the domestic surgical robot sector, which has seen a wave of IPO attempts following the successful listing of MicroPort Robotics in 2021 [3][4]. - Shurui Robot is recognized as a leading startup in the surgical robot field, with Xu Kai having nearly 20 years of experience in this domain [5][6]. Technological Advancements - The company has developed a series of key technologies and core components, including a revolutionary design known as the "deformable dual-continuum mechanism," which enhances the performance of its surgical robots [6]. - Shurui Robot's single-port laparoscopic surgical robot became the first in China to pass the special review process for innovative medical devices in 2020 and received approval from the National Medical Products Administration (NMPA) in June 2023 [7]. Market Position and Financing - The company has completed six rounds of financing from 2019 to 2023, attracting notable venture capital firms such as Shunwei Capital and Medtronic [8]. - As of April 2025, Shurui Robot has filed over 805 patents globally, establishing a comprehensive intellectual property protection system [7].

Core Insights - A profound revolution in artificial intelligence is approaching, with China's robotics industry accelerating its development [1] - Beijing is emerging as a hub for robotics innovation, with over 400 key robotics companies and leading positions in humanoid robot manufacturing [3][5] - The robotics industry is increasingly integrating into various sectors, showcasing significant advancements in technology and applications [5][7] Industry Development - Beijing has implemented initiatives like the "Hundred Robot New Products Project" and "Hundred Application Scenarios Demonstration Project" to foster innovation and application in robotics [5] - The surgical robot developed by Beijing Shurui Robotics has received national approval and has been used in over 1,500 surgeries across more than 70 hospitals, enhancing precision and reducing patient trauma [7] - In 2024, the revenue of Beijing's robotics industry is projected to exceed 30 billion, marking a nearly 50% year-on-year growth [7] Market Potential - The humanoid robot market in China is expected to reach approximately 870 billion by 2030, indicating significant growth potential [8] - The humanoid robot sector is anticipated to see rapid advancements in capabilities, with a focus on industrial, commercial, and domestic applications starting from 2024 [10] - The global humanoid robot market is increasingly competitive, with Chinese companies accounting for over one-third of the top 100 humanoid robot firms worldwide [7][8] Innovation and Competition - The first humanoid robot half-marathon in Beijing attracted global attention and led to a surge in orders for participating companies, highlighting the competitive landscape [10][12] - The establishment of a humanoid robot 4S store in Beijing aims to provide comprehensive lifecycle services for robots, enhancing the industry's infrastructure [12] - Continuous policy support and an optimized development environment are driving the growth of robotics companies in Beijing, positioning the city as a global leader in the robotics industry [12]

Core Viewpoint - The surgical robot market in China is experiencing significant growth, with a 82.9% year-on-year increase in the number of surgical robots awarded contracts in the first five months of 2025, despite some companies facing bankruptcy and liquidation [1] Group 1: Market Dynamics - The surgical robot industry is highly competitive, with numerous domestic companies participating in various segments, including over 16 approved laparoscopic surgical robots and more than 50 orthopedic surgical robots [1] - The number and amount of financing in the surgical robot sector have sharply decreased, leading to potential funding crises for companies that have not yet achieved commercial revenue [1][3] - The market is witnessing a price war among companies, with various surgical robots being commercialized at significantly different price points, yet the market leader, the Da Vinci surgical robot, remains unaffected in terms of sales [4][5] Group 2: Clinical and Technological Challenges - Some surgical robots are limited to simple procedures, and their clinical value has not yet been fully realized, as evidenced by a study showing that 11% of robot-assisted coronary interventions required conversion to manual operation [2][4] - The commercial success of surgical robots is heavily influenced by policies and macroeconomic conditions, with some companies experiencing significant declines in sales and revenue due to factors like anti-corruption measures and slowed bidding processes [5] Group 3: Innovations and Strategies - Companies are focusing on technological innovations, including the integration of AI to enhance the capabilities of surgical robots, with several firms already developing AI-enabled products [8][9] - Efforts are being made to reduce product costs to make surgical robots more accessible to hospitals, such as the modular design of the HaiShan laparoscopic surgical robot [9] - Companies are exploring remote surgical technologies to expand their market reach and improve access to quality healthcare, with several firms successfully conducting remote surgeries [9][10] Group 4: Market Expansion and Accessibility - Surgical robot companies are increasingly looking to international markets for growth, with firms like MicroPort achieving significant revenue increases through overseas orders [12] - There is a trend of surgical robots being adopted in county-level hospitals, which allows for more complex procedures to be performed locally, thus improving healthcare access for patients [14][15]